# Fecal Noninvasive Biomarkers Oriented Control Versus Usual Care Strategy in Ulcerative Colitis

> **NCT07402135** · NA · NOT_YET_RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 240 (estimated)

## Conditions studied

- Noninvasive Biomarkers
- Ulcerative Colitis (UC)

## Interventions

- **PROCEDURE:** Preemptive therapy escalation based on preset thresholds (FC >250 μg/g or FIT >100 ng/mL) using the FOCUS-UC Ladder:
- **PROCEDURE:** Therapy adjustment only upon clinical relapse (pMS increase ≥2 + rectal bleeding score ≥1).

## Key facts

- **NCT ID:** NCT07402135
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07402135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07402135, "Fecal Noninvasive Biomarkers Oriented Control Versus Usual Care Strategy in Ulcerative Colitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07402135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*